Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorGrauslund, Jakob
dc.contributor.authorFrydkjaer-Olsen, Ulrik
dc.contributor.authorPeto, Tunde
dc.contributor.authorFernández-Carneado, Jimena
dc.contributor.authorPonsati, Berta
dc.contributor.authorHernández Pascual, Cristina
dc.contributor.authorSimó Canonge, Rafael
dc.date.accessioned2019-07-09T05:47:25Z
dc.date.available2019-07-09T05:47:25Z
dc.date.issued2019-05-01
dc.identifier.citationGrauslund J, Frydkjaer-Olsen U, Peto T, Fernández-Carneado J, Ponsati B, Hernández C, et al. Topical Treatment With Brimonidine and Somatostatin Causes Retinal Vascular Dilation in Patients With Early Diabetic Retinopathy From the EUROCONDOR. Investig Opthalmology Vis Sci. 2019;60(6):2257-62.
dc.identifier.issn0146-0404
dc.identifier.urihttp://hdl.handle.net/11351/4185
dc.descriptionDiabetic retinopathy; Brimonidine; Vascular dilation
dc.description.abstractStructural retinal microvascular changes have been identified as risk markers of diabetic retinopathy (DR). In order to estimate the retinal response of neuroprotective eye drops, we aimed to evaluate the effect of topical retinal neuroprotection on retinal microvascular changes in early DR. METHODS: Patients with type 2 diabetes with no or early DR were randomized 1:1:1 to topical treatment with placebo, brimonidine, or somatostatin in a 96-week prospective, phase II to III, European multicenter trial. Retinal vascular calibers were measured semiautomatically in digital fundus images by certified graders at baseline and follow-up and summarized as central retinal arteriolar and venular equivalent (CRAE and CRVE). RESULTS: Of 449 patients originally included, 297 completed the study with gradable retinal images. Median age and duration of diabetes was 64.5 and 9.9 years, and 65.7% were male. At baseline, Early Treatment Diabetic Retinopathy Study levels were 10 (no DR, 42.8%), 20 (minimal DR, 28.3%), and 35 (mild DR, 29.0%), and CRAE and CRVE did not differ between groups. As opposed to patients with no or minimal DR at baseline, patients with mild DR in the active groups developed a larger retinal arteriolar (brimonidine: +6.2 μm, P = 0.006; somatostatin: +7.2 μm, P = 0.006) and venular (brimonidine: +13.9 μm, P = 0.01; somatostatin: +14.3 μm, P = 0.0001) caliber in contrast to those in the placebo group. CONCLUSIONS: Topical treatment with brimonidine and somatostatin causes retinal arteriolar and venular dilation in patients with type 2 diabetes and preexisting early DR. Upcoming studies should elaborate on the potential of these findings in arresting early DR.
dc.language.isoeng
dc.publisherAssociation for Research in Vision and Ophthalmology
dc.relation.ispartofseriesInvestigative Ophthalmology & Visual Science;60(6)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectRetinopatia diabètica - Tractament
dc.subjectSomatostatina
dc.subjectCompostos heterocíclics
dc.subjectVasodilatadors
dc.subject.meshDiabetic Retinopathy
dc.subject.mesh/drug therapy
dc.subject.meshBrimonidine Tartrate
dc.subject.meshSomatostatin
dc.subject.mesh/drug effects
dc.titleTopical Treatment With Brimonidine and Somatostatin Causes Retinal Vascular Dilation in Patients With Early Diabetic Retinopathy From the EUROCONDOR
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1167/iovs.18-26487
dc.subject.decsretinopatía diabética
dc.subject.decs/tratamiento farmacológico
dc.subject.decstartrato de brimonidina
dc.subject.decssomatostatina
dc.subject.decs/efectos de los fármacos
dc.relation.publishversionhttps://iovs.arvojournals.org/article.aspx?articleid=2734637
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Grauslund J] Department of Ophthalmology, Odense University Hospital, Odense, Denmark. Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark. [Frydkjaer-Olsen U] Department of Ophthalmology, Odense University Hospital, Odense, Denmark. Department of Clinical Research, University of Southern Denmark, Odense, Denmark. [Peto T] Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Centre for Public Health, Institute of Clinical Sciences, Queen's University Belfast, Belfast, United Kingdom. [Fernández-Carneado J, Ponsati B] BCN Peptides, Barcelona, Spain. [Hernández C, Simó R] Grup de recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Hospital Universitari Vall d'Hebron, Barcelona, Spain.
dc.identifier.pmid31112610
dc.identifier.wosWOS:000468980600051
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record